Seelos_full logo and icon color.jpg
Seelos Therapeutics to Participate in 33rd Annual National MPS Society Family Conference
13 déc. 2019 08h30 HE | Seelos Therapeutics, Inc.
NEW YORK, Dec. 13, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005) 
04 déc. 2019 08h00 HE | Seelos Therapeutics, Inc.
NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Reports Q3 2019 Pipeline Update
08 nov. 2019 07h00 HE | Seelos Therapeutics, Inc.
NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, today released its third quarter pipeline update. “Seelos continued...
Seelos_full logo and icon color.jpg
Seelos Therapeutics to Participate in Upcoming Investor Conference in November
18 oct. 2019 09h00 HE | Seelos Therapeutics, Inc.
NEW YORK, Oct. 18, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it will participate in the Jefferies 2019...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Announces the Addition of Scott Applebaum as Lead Strategic Regulatory Consultant
15 oct. 2019 09h00 HE | Seelos Therapeutics, Inc.
NEW YORK, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, today announced the addition of Scott Applebaum to its team as lead...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Announces Pricing of $6.7 Million Registered Direct Offering
23 août 2019 09h00 HE | Seelos Therapeutics, Inc.
NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it has entered into a securities purchase...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Announces FDA Acceptance of IND Application for SLS-005 for Mucopolysaccharidosis Type III (Sanfilippo Syndrome)
22 août 2019 09h00 HE | Seelos Therapeutics, Inc.
NEW YORK, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, is pleased to announce the acceptance of the Investigation New Drug...
Seelos_full logo and icon color.jpg
Seelos Therapeutics to Ring Opening Bell at Nasdaq on August 12th
06 août 2019 09h00 HE | Seelos Therapeutics, Inc.
NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that Raj Mehra, PhD, Chairman, Founder, and CEO of...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Announces Investigational New Drug Application Submission for SLS-005
17 juil. 2019 09h00 HE | Seelos Therapeutics, Inc.
NEW YORK, July 17, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that it has submitted an Investigational New Drug...